HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Infectious Disease
RCT
HIV-1 resistance patterns vary by prior regimen and geographic region in this substudy
HIV drug resistance patterns vary by region and prior treatment history
This substudy examined HIV-1 drug resistance mutations in people failing first-line therapy across 14 countries.
HIV drug resistance varies by region and prior treatment. Subtype C dominates, but resistance to common drugs is high. This matters for choo…
May 1, 2026
Infectious Disease
Phase I
Islatravir and lenacapavir fixed-dose combination shows similar bioavailability to single agents in healthy volunteers
New HIV pill works with or without food in early safety tests
This open-label phase 1 study enrolled 93 people without HIV to assess the oral relative bioavailability and safety of a fixed-dose combinat…
A new HIV pill containing islatravir and lenacapavir showed similar drug levels whether taken with food or on an empty stomach, supporting f…
May 1, 2026
Allergy & Immunology
HIV-2 diagnoses remain low in the United States, differentiation test use studied
HIV-2 diagnoses remain low in the United States, report finds
A U.S. report on trends in HIV-2 diagnoses and HIV-1/HIV-2 differentiation test use found diagnoses of HIV-2 remain low.
HIV-2 diagnoses stay low in the U.S., but current testing methods could be updated to work better.
CDC
Apr 4, 2026
Allergy & Immunology
Phase III
Phase 3 trial compares switch to doravirine/islatravir versus continuing bictegravir/FTC/TAF in HIV-1
Phase 3 trial compares two HIV drug regimens for people already virologically suppressed
A phase 3 randomized controlled trial enrolled 643 virologically suppressed adults with HIV-1 to compare switching to doravirine/islatravir …
People with HIV already on effective treatment can safely switch to a new two-drug pill without losing virus control, according to a complet…
CT.gov
Apr 2, 2026
Infectious Disease
RCT
Bictegravir-lenacapavir single-tablet regimen non-inferior to complex regimens for HIV-1 suppression at 48 weeks
Can a single daily pill control HIV as well as complex multi-pill regimens?
In this phase 3 randomized trial of 557 virologically suppressed adults with HIV-1 on complex regimens, switching to once-daily oral…
A new single daily pill kept HIV suppressed just as well as complex multi-pill regimens in a trial of 557 adults who had been on treatment f…
Mar 30, 2026